晨光生物(300138) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 reached ¥1,734,499,040.21, an increase of 15.58% compared to the same period last year[2] - Net profit attributable to shareholders was -¥37,228,735.86, a decrease of 137.34% year-on-year[2] - Net profit excluding non-recurring items was -¥65,485,036.37, down 172.68% from the previous year[2] - The net profit for Q3 2024 was CNY 45,240,156.78, a significant decrease from CNY 416,111,137.75 in the same period last year, representing a decline of approximately 89.1%[21] - The total profit before tax was CNY 74,352,639.96, down from CNY 471,149,241.11 in the same quarter last year, reflecting a decline of about 84.3%[21] - The total comprehensive income for the period was CNY 38,732,653.47, a decrease from CNY 429,534,028.97 in the previous year, representing a decline of about 91%[21] Assets and Liabilities - Total assets decreased by 9.25% to ¥7,749,738,238.17 compared to the end of the previous year[3] - Shareholders' equity attributable to the parent company decreased by 11.68% to ¥3,065,164,116.02[3] - Total liabilities decreased to ¥4,640,991,667.99 from ¥5,007,327,600.82, a reduction of approximately 7.31%[19] - Non-current assets totaled ¥2,184,311,145.62, slightly up from ¥2,172,731,507.62, showing a growth of about 0.53%[19] - Short-term borrowings decreased to ¥2,162,000,342.62 from ¥2,598,920,737.98, a decline of about 16.86%[19] - The company reported a decrease in accounts payable to ¥70,860,420.88 from ¥79,531,391.70, representing a reduction of approximately 10.93%[19] Cash Flow - Cash flow from operating activities for the year-to-date increased by 61.02% to ¥1,603,186,609.10[2] - Net cash flow from operating activities increased by 61.02% year-on-year, driven by a decrease in raw material procurement[8] - The cash flow from operating activities netted CNY 1,603,186,609.10, an increase from CNY 995,638,605.50 in the prior year, reflecting a growth of approximately 60.9%[22] - Investment activities generated a net cash flow of CNY 215,204,783.54, a turnaround from a negative cash flow of CNY -18,319,902.96 in the same period last year[23] - Cash flow from financing activities decreased by 297.66% year-on-year, as cash outflows for loan repayments and share buybacks exceeded inflows[10] Expenses and Financial Performance - Financial expenses increased by 90.60% year-on-year, with interest expenses rising by 37.55% due to an increase in loan scale[8] - The company incurred financial expenses of CNY 53,928,133.24, up from CNY 28,293,622.86 in the previous year, marking an increase of about 90.5%[21] - Research and development expenses for the period were ¥72,436,744.27, up from ¥61,110,369.60, indicating an increase of approximately 18.93%[20] - Operating profit, total profit, net profit, and net profit attributable to shareholders decreased by 87.04%, 84.22%, 89.13%, and 84.28% respectively, mainly due to increased operating costs and reduced investment income[8] Inventory and Receivables - Inventory decreased by 46.22% compared to the beginning of the year, primarily due to lower sales and the timing of raw material procurement[7] - Other receivables increased by 142.88% year-to-date, mainly due to financial assistance provided to joint ventures[7] - The company's inventory at the end of the reporting period remained at a reasonable and healthy level[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,170, with the top ten shareholders holding significant stakes[11] - The company repurchased a total of 49.6739 million shares, accounting for 9.32% of the total share capital, with a total transaction amount of RMB 492 million[16] Business Performance - The company achieved a revenue of RMB 5.225 billion in the first three quarters, representing a year-on-year growth of 1.08%[15] - The revenue from plant extract business reached RMB 2.328 billion, with a year-on-year increase of 11.11%[15] - The sales volume of chili red pigment was 6,573 tons, a decrease of 14.35% year-on-year[15] - The sales volume of lutein reached 330 million grams, marking a new high for the period[15] - The revenue from stevia continued to grow rapidly, achieving RMB 182 million in the first three quarters, a new high for the period[15] - The gross margin for plant extract business was 15.95%, down 6.12% year-on-year[15] - The company plans to develop over 200,000 acres of marigold planting bases domestically and internationally in 2024[15]